

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/006,265	12/03/2001	Masatsugu Maeda	14875-096001/C2-105DP1P	5055
26161 7590 07/30/2007 FISH & RICHARDSON PC P.O. BOX 1022			EXAMINER WEHBE, ANNE MARIE SABRINA	
		,	1633	
			MAIL DATE	DELIVERY MODE
			07/30/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/006,265	MAEDA ET AL.		
Examiner	Art Unit		
Anne Marie S. Wehbe	1633		

	Anne Marie S. Wehbe	1633	
The MAILING DATE of this communication appe	ears on the cover sheet with the c	correspondence addre	ess
THE REPLY FILED <u>22 June 2007</u> FAILS TO PLACE THIS API	PLICATION IN CONDITION FOR A	LLOWANCE.	
1. The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follo places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in complian time periods:	n the same day as filing a Notice of wing replies: (1) an amendment, affortice of Appeal (with appeal fee) in c	Appeal. To avoid aband fidavit, or other evidence compliance with 37 CFF	e, which R 41.31; or (3)
<ul> <li>a)</li></ul>	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailin (b). ONLY CHECK BOX (b) WHEN THE 106.07(f).	g date of the final rejection E FIRST REPLY WAS FIL	i. ED WITHIN
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	ctension and the corresponding amount shortened statutory period for reply orig to than three months after the mailing da	of the fee. The appropriat	e extension fee action: or (2) as
<ol> <li>The Notice of Appeal was filed on A brief in com filing the Notice of Appeal (37 CFR 41.37(a)), or any external a Notice of Appeal has been filed, any reply must be filed AMENDMENTS</li> </ol>	ension thereof (37 CFR 41.37(e)), to	avoid dismissal of the	of the date of appeal. Since
3. The proposed amendment(s) filed after a final rejection,  (a) They raise new issues that would require further co  (b) They raise the issue of new matter (see NOTE below)  (c) They are not deemed to place the application in be appeal; and/or  (d) They present additional claims without canceling a	onsideration and/or search (see NO ow); etter form for appeal by materially re	TE below); educing or simplifying th	
NOTE: (See 37 CFR 1.116 and 41.33(a)) 4.  The amendments are not in compliance with 37 CFR 1.1 5.  Applicant's reply has overcome the following rejection(s 6.  Newly proposed or amended claim(s) would be a	121. See attached Notice of Non-Co ): <u>see attached.</u> .	ompliant Amendment (P	
non-allowable claim(s).  7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is protected. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: 1,3,5,7 and 20-23.  Claim(s) objected to:Claim(s) rejected: 2,4,6 and 8.  Claim(s) withdrawn from consideration: 9-19 and 28-31.	☐ will not be entered, or b) ⊠ wi ovided below or appended.	Il be entered and an ex	planation of
AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good ar was not earlier presented. See 37 CFR 1.116(e).	ut before or on the date of filing a N nd sufficient reasons why the affidav	otice of Appeal will <u>not</u> vit or other evidence is ı	be entered necessary and
9.  The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessa 10.  The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	overcome <u>all</u> rejections under appe ry and was not earlier presented. S	al and/or appellant fails See 37 CFR 41.33(d)(1)	to provide a
<ul> <li>11.  The request for reconsideration has been considered be see attached</li> <li>12.  Note the attached Information Disclosure Statement(s).</li> </ul>		n condition for allowand	e because:
13. ☐ Other:			

## **Attachment to Advisory Action**

**5. cont.** Applicant's amendment canceling claims 24-27 overcomes the previous grounds of rejection of these claims under 35 U.S.C. 112, first paragraph, for lack of enablement.

11. cont. The amendment to claim 2, deleting SEQ ID NO:17 as an embodiment of the claim, fails to overcome the rejection of claims 2, 4, 6, and 8 under 35 U.S.C. 102(e) over U.S. Patent No. 6,747,137, Weinstock et al. The applicant argues that as the claims are now limited to fragments of SEQ ID NOS 2 or 4, the rejection has been overcome. However, SEQ ID NO:3111 of Weinstock et al. continues to anticipate the claims as written. The same 9mer sequence taught by Weinstock is present not only in SEQ ID NO:17, but also in SEQ ID NOS: 2 and 4, see attached alignments. Thus, deleting SEQ ID NO:17 does not overcome this grounds of rejection, as it applies equally to nucleic acids encoding a fragment of at least 7 amino acids of SEQ ID NOS: 2 and 4 as well.

Anne Marie S. Wehbé, Ph.D., whose telephone number is (571) 272-0737. If the examiner is not available, the examiner's supervisor, Joseph Woitach, can be reached at (571) 272-0739. For all official communications, the new technology center fax number is (571) 273-8300. Please note that all official communications and responses sent by fax must be directed to the technology

Application/Control Number: 10/006,265

Art Unit: 1633

center fax number. For informal, non-official communications only, the examiner's direct fax

Page 3

number is (571) 273-0737. For any inquiry of a general nature, please call (571) 272-0547.

The applicant can also consult the USPTO's Patent Application Information Retrieval

system (PAIR) on the internet for patent application status and history information, and for

electronic images of applications. For questions or problems related to PAIR, please call the

USPTO Patent Electronic Business Center (Patent EBC) toll free at 1-866-217-9197.

Representatives are available daily from 6am to midnight (EST). When calling please have your

application serial number or patent number available. For all other customer support, please call

the USPTO call center (UCC) at 1-800-786-9199.

Dr. A.M.S. Wehbé

/Anne Marie S. Wehbé/

Primary Examiner, A.U. 1633

```
10006625notes.txt
 Sequence 3111, Application US/09248796A
 Patent No. 6747137
  GENERAL INFORMATION:
   APPLICANT: Keith Weinstock et al
  TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA
ALBICANS
  TITLE OF INVENTION: FOR DIAGNOSTICS AND THERAPEUTICS
   FILE REFERENCE: 107196.132
   CURRENT APPLICATION NUMBER: US/09/248.796A
   CURRENT FILING DATE: 1999-02-12
   PRIOR APPLICATION NUMBER: US 60/074,725
   PRIOR FILING DATE: 1998-02-13
   PRIOR APPLICATION NUMBER: US 60/096,409 PRIOR FILING DATE: 1998-08-13
   NUMBER OF SEQ ID NOS: 28208
  SEQ ID NO 3111
    LENGTH: 597
    TYPE: DNA
    ORGANISM: Candida albicans
US-09-248-796A-3111
Alignment Scores:
Pred. No.:
                         5.45
                                                         597
                                         Length:
Score:
                         9.00
                                         Matches:
                                                         q
Percent Similarity:
                         100.00%
                                                         0
                                         Conservative:
Best Local Similarity:
                         100.00%
                                                         0
                                         Mismatches:
Query Match:
                         1.38%
                                         Indels:
                                                         0
DR:
                         4
                                         Gaps:
US-10-006-265-2 (1-652) x US-09-248-796A-3111 (1-597)
           80 AsnCysThrThrAsnSerSerThrSer 88
Qy
               111111111111111111111111111111
Db
           81 AACTGTACCACCAACAGCAGCACTAGC 55
US-09-248-796A-3111/c
  Sequence 3111, Application US/09248796A
  Patent No. 6747137
  GENERAL INFORMATION:
   APPLICANT: Keith Weinstock et al
   TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA
ALBICANS
   TITLE OF INVENTION: FOR DIAGNOSTICS AND THERAPEUTICS
   FILE REFERENCE: 107196.132
   CURRENT APPLICATION NUMBER: US/09/248,796A
   CURRENT FILING DATE: 1999-02-12
   PRIOR APPLICATION NUMBER: US 60/074,725
   PRIOR FILING DATE: 1998-02-13
   PRIOR APPLICATION NUMBER: US 60/096,409
   PRIOR FILING DATE: 1998-08-13
  NUMBER OF SEQ ID NOS: 28208 SEQ ID NO 3111
    LENGTH: 597
    TYPE: DNA
    ORGANISM: Candida albicans
ÚS-09-248-796A-3111
Alignment Scores:
Pred. No.:
                         2.24
                                         Length:
                                                         597
                                         Page 1
```

Score: Percent Similarity: Best Local Similarity: Query Match: DB:	9.00 100.00% 100.00% 3.57%	10006625notes.txt	9000
US-10-006-265-4 (1-252)	x US-09-2	48-796A-3111 (1-597)	
Qy 80 AsnCysThr	ThrAsnSerS	erThrSer 88	
	1111111111		